A5085950371- HIV/AIDS Research and Interventions
- Vaccine Coverage and Hesitancy
- Meta-analysis and systematic reviews
- Statistical Methods and Bayesian Inference
- Statistical Methods in Clinical Trials
- HIV Research and Treatment
- SARS-CoV-2 and COVID-19 Research
- Adolescent Sexual and Reproductive Health
- HIV-related health complications and treatments
- Bacterial Infections and Vaccines
- Advanced Causal Inference Techniques
- Pneumonia and Respiratory Infections
- Animal Virus Infections Studies
- COVID-19 Clinical Research Studies
- Reproductive Health and Contraception
Fred Hutch Cancer Center
2018-2025
University of Washington
2022
Cancer Research Center
2021
MRC Biostatistics Unit
2018
Although the three vaccines against coronavirus disease 2019 (Covid-19) that have received emergency use authorization in United States are highly effective, breakthrough infections occurring. Data needed on serial of homologous boosters (same as primary vaccine) and heterologous (different from fully vaccinated recipients.In this phase 1-2, open-label clinical trial conducted at 10 sites States, adults who had completed a Covid-19 vaccine regimen least 12 weeks earlier no reported history...
While Coronavirus disease 2019 (Covid-19) vaccines are highly effective, breakthrough infections occurring. Booster vaccinations have recently received emergency use authorization (EUA) for certain populations but restricted to homologous mRNA vaccines. We evaluated and heterologous booster vaccination in persons who had an EUA Covid-19 vaccine regimen. In this phase 1/2 open-label clinical trial conducted at ten U.S. sites, adults one of three least 12 weeks prior enrollment no reported...
In a network meta‐analysis, between‐study heterogeneity variances are often very imprecisely estimated because data sparse, so standard errors of treatment differences can be highly unstable. External evidence provide informative prior distributions for and, hence, improve inferences. We explore approaches specifying priors multiple in meta‐analysis. First, we assume equal across all pairwise intervention comparisons (approach 1); incorporating an the common variance is then straightforward....
Background: The monthly dapivirine vaginal ring provides partial protection against HIV, and a longer duration may reduce user burden improve adherence. We examined acceptability preference for 3-month versus 1-month rings HIV-1 risk reduction in phase 1 clinical trial. Materials Methods: In Microbicide Trials Network-036/International Partnership Microbicides 047, 49 HIV-negative participants aged 18-45 were randomized to one of two or the ring. Acceptability ratings collected at...
Abstract The availability of effective Pre-Exposure Prophylaxis (PrEP) for HIV introduces new challenges testing novel on-demand, user-controlled prevention products, including lower placebo arm incidence and increased between-participant variability in risk. In this paper, we discuss how low may result longer trials which the participants' risk impact estimate reduction. We introduce a measure per-exposure efficacy that be more relevant than population level reduction on demand products...
Using the MTN-020/ASPIRE HIV prevention trial as a motivating example, our objective is to construct joint model for exposure process through vaginal intercourse and time infection in population of sexually active women. By modeling participants' terms exposures, rather than exposed, aim obtain valid estimate per-act efficacy preventive intervention. Within context trials, which frequency sex acts self-reported periodically by participants, we participants with non-homogeneous Poisson...